226 related articles for article (PubMed ID: 26466824)
1. Evaluation of The Cervista HPV A9 group In Screening Patients for Cervical Cancer.
Zhao J; Du H; Belinson JL; Qu X; Zhang W; Mei J; Yang B; Wang C; Zhang L; Wu R
J Med Screen; 2016 Mar; 23(1):38-43. PubMed ID: 26466824
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of careHPV, Cervista Human Papillomavirus, and Hybrid Capture 2 Methods in Diagnosing Cervical Intraepithelial Neoplasia Grade 2+ in Xinjiang Uyghur Women.
Tuerxun G; Yukesaier A; Lu L; Aierken K; Mijiti P; Jiang Y; Abulizi A; Zhang Y; Abuduxikuer G; Abulizi G; Li H
Oncologist; 2016 Jul; 21(7):825-31. PubMed ID: 27317575
[TBL] [Abstract][Full Text] [Related]
3. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
Zhang H; Varma KR; Han M; Matsko J; Zhao C
Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
[TBL] [Abstract][Full Text] [Related]
4. Triage of women with negative cytology and positive high-risk HPV: an analysis of data from the SHENCCAST II/III studies.
Goodrich SK; Pretorius RG; Du H; Wu R; Belinson JL
J Low Genit Tract Dis; 2014 Apr; 18(2):122-7. PubMed ID: 24270196
[TBL] [Abstract][Full Text] [Related]
5. Clinical performance characteristics of the Cervista HPV HR test kit in cervical cancer screening in China.
Zhao J; Zhang X; Ma J; Liu G; Yao D; Zhang W; Wang J; Wei L; Zhao Y; Zeng Y; Liao Q
J Low Genit Tract Dis; 2012 Oct; 16(4):358-63. PubMed ID: 23023138
[TBL] [Abstract][Full Text] [Related]
6. A new PCR-based mass spectrometry system for high-risk HPV, part II: clinical trial.
Du H; Yi J; Wu R; Belinson SE; Qu X; Yang B; Wang C; Yi X; Belinson JL
Am J Clin Pathol; 2011 Dec; 136(6):920-3. PubMed ID: 22095378
[TBL] [Abstract][Full Text] [Related]
7. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
[TBL] [Abstract][Full Text] [Related]
8. [Performance of vaginal self-sampling high-risk HPV genotyping as primary and combining cytology or viral load as secondary in cervical cancer screening].
Guo CL; Luo HX; Wang C; Qu XF; Yang B; Belinson JL; Du H; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2021 Apr; 56(4):271-279. PubMed ID: 33902239
[No Abstract] [Full Text] [Related]
9. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
[TBL] [Abstract][Full Text] [Related]
10. Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.
Guo M; Shlyakhova N; Khanna A; Tinnirello AA; Schmeler KM; Hwang J; Sturgis EM; Stewart J
J Am Soc Cytopathol; 2021; 10(4):399-405. PubMed ID: 33967024
[TBL] [Abstract][Full Text] [Related]
11. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of the effectiveness of BMRT-HPV for cervical cancer screening].
Duan LF; Du H; Wang C; Huang X; Qu XF; Duan XZ; Liu Y; Shi B; Zhang W; Wei LH; Belinson L; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2020 Oct; 55(10):708-715. PubMed ID: 33120484
[No Abstract] [Full Text] [Related]
13. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
15. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
16. A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off.
Boehmer G; Wang L; Iftner A; Holz B; Haedicke J; von Wasielewski R; Martus P; Iftner T
BMC Infect Dis; 2014 Dec; 14():674. PubMed ID: 25487281
[TBL] [Abstract][Full Text] [Related]
17. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
[TBL] [Abstract][Full Text] [Related]
18. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
[TBL] [Abstract][Full Text] [Related]
20. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
